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Abstract 84 
Context: Lower thyroid-stimulating hormone (TSH) screening cut-offs have doubled the 85 
ascertainment of congenital hypothyroidism (CH), particularly cases with a eutopically-located gland-86 
in-situ (GIS). Although mutations in known dyshormonogenesis genes, or the thyroid-stimulating 87 
hormone receptor (TSHR) underlie some cases of CH with GIS, systematic screening of these eight 88 
genes has not previously been undertaken. 89 
 90 
Objective: To evaluate the contribution and molecular spectrum of mutations in eight known 91 
causative genes (TG, TPO, DUOX2, DUOXA2, SLC5A5, SLC26A4, IYD and TSHR) in CH cases with 92 
GIS. 93 
 94 
Patients, Design and Setting: We screened forty-nine CH cases with GIS from thirty-four ethnically 95 
diverse families, using next-generation sequencing. Pathogenicity of novel mutations was assessed in 96 
silico. 97 
 98 
Results: Twenty-nine cases harbored likely disease-causing mutations. Monogenic defects (nineteen 99 
cases) most commonly involved TG (twelve), TPO (four), DUOX2 (two) and TSHR (one case). Ten 100 
cases harboured triallelic (digenic) mutations: TG and TPO (one); SLC26A4 and TPO (three) and 101 
DUOX2 and TG (six cases). Novel variants overall included fifteen TG, six TPO, and three DUOX2 102 
mutations. Genetic basis was not ascertained in twenty patients, including fourteen familial cases. 103 
 104 
Conclusions: The aetiology of CH with GIS remains elusive, with only 59% attributable to mutations 105 
in TSHR or known dyshormonogenesis-associated genes in a cohort enriched for familial cases. 106 
Biallelic TG or TPO mutations most commonly underlie severe CH. Triallelic defects are frequent, 107 
mandating future segregation studies in larger kindreds to assess their contribution to variable 108 
phenotype. A high proportion (~41%) of unsolved or ambiguous cases suggests novel genetic 109 
aetiologies that remain to be elucidated. 110 
 111 
 5 
Introduction 112 
 113 
Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, and historically 114 
thyroid dysgenesis was thought to account for approximately 80% of cases (1).  However, recent 115 
studies have reported a change in the epidemiology of CH, with a doubling in incidence to around 1 in 116 
1500 live newborns, predominantly driven by an increase in CH with eutopic GIS, which accounted 117 
for almost two-thirds of recently diagnosed cases in Lombardy, Italy (2). Lower TSH screening cut-118 
offs may be the major driver for this increase in diagnosis although altered ethnicities of the screened 119 
population, increased multiple and premature births, iodine status and hitherto uncharacterized factors 120 
may also contribute (3, 4). 121 
 122 
The molecular basis of CH with GIS remains poorly understood (5, 6). Genetic variation in seven 123 
genes involved in thyroid hormone biosynthesis (TG, TPO, DUOX2, DUOXA2, IYD, SLC5A5 and 124 
SLC26A4) and TSHR mediates some cases. Disease-causing mutations are usually biallelic, with the 125 
exception of monoallelic DUOX2, IYD and TSHR mutations, which may also confer a phenotype (1). 126 
Phenotypic heterogeneity in cases harbouring similar causative mutations suggests that mono and 127 
polygenic factors and environmental modulators may also play a role in determining disease severity 128 
(7, 8).  129 
 130 
Genetic characterization of CH with GIS has been limited by the cost and labour implications of 131 
Sanger sequencing multiple exons. Previous studies have generally focused on either a small number 132 
of genes (e.g. TG, TPO, TSHR and DUOX2 in 43 Korean cases) (6), specific phenotypic subsets of 133 
cases (5, 8) or multiple genes in a small subset of patients (9). There are occasional reports of digenic 134 
mutations involving TSHR and either DUOX2 (6, 10, 11) or TPO (12), or combined DUOX2 and 135 
DUOXA2 mutations (13). However, the role of oligogenicity in disease development and penetrance 136 
remains unclear, with no evidence for an additive effect of digenic mutations in one large published 137 
kindred (12). 138 
 139 
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Next-generation sequencing (NGS) technologies increase sequencing capacity and speed, enabling 140 
efficient screening of multiple genes simultaneously. A recent publication describes large-scale 141 
multiplexed genetic screening of TPO, TSHR, DUOX2, DUOXA2, PAX8 and SLC5A5 in 170 Korean 142 
CH cases. However, cases were from a single ethnic background and not selected on the basis of 143 
thyroid morphology; moreover TG, IYD and SLC26A4 were not sequenced (11). We undertook 144 
comprehensive screening of TG, TPO, DUOX2, DUOXA2, IYD, SLC5A5, SLC26A4 and TSHR in an 145 
ethnically and biochemically heterogeneous CH cohort with GIS. As well as reporting known and 146 
novel mutations in these genes, we document the frequent occurrence of potential oligogenicity, with 147 
triallelic variation in two candidate genes, in a population enriched for familial and consanguineous 148 
cases.  149 
 150 
Patients and Methods 151 
Patients 152 
All investigations were part of an ethically approved protocol and/or clinically indicated, being 153 
undertaken with written informed consent from patients and/or next of kin including specific consent 154 
for WES (MREC 98/5/024). Forty-nine cases were included in the study, from thirty-four families 155 
referred from centers in the UK, Oman, Saudi Arabia, UAE and Turkey. Inclusion required clinical 156 
evidence of goitre or radiological evidence of a normally-sited thyroid gland in the proband. In five 157 
cases without goiter who had not undergone thyroid imaging at diagnosis, we accepted goiter or 158 
radiological evidence of GIS in at least one affected family member with CH, assuming a common 159 
underlying genetic aetiology. A diagnosis of overt or subclinical primary congenital hypothyroidism 160 
was made on the basis of referral through newborn screening and/or a raised venous TSH. Newborn 161 
screening blood spot cut offs were as follows: 6-10mU/L (UK), 10mU/L (UAE) or cord blood TSH 162 
40mU/L (Oman). Childhood TSH normal range was 0.35-5.5mU/L. Thyroid biochemistry was 163 
measured using local analyzers in the referring hospitals. 164 
 165 
DNA sequencing 166 
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Three different NGS-based strategies (whole-exome sequencing, WES, and two different targeted 167 
sequencing protocols) were used to screen Thyroglobulin (TG), Thyroid peroxidase (TPO), Thyroid 168 
stimulating hormone receptor (TSHR), Dual oxidase 2, (DUOX2), Dual oxidase maturation factor 2 169 
(DUOXA2), Iodotyrosine deiodinase (IYD), solute carrier family 5,  member 5, NIS (SLC5A5) and 170 
Solute carrier family 26 member 4, Pendrin (SLC26A4). Detailed methods, coverage and quality 171 
control data is available in the Supplementary methods and results. We sought to identify rare variants 172 
(MAF <0.02 in all control databases) with likely pathogenic consequences predicted by in silico 173 
algorithms. Given the ethnic heterogeneity of our cohort we selected the maximum number of control 174 
exomes (n~80, 000) matched as closely for ethnicity as we could achieve (Supplementary methods). 175 
All positive results were validated by Sanger sequencing. 176 
 177 
Nomenclature 178 
Variants were described using nomenclature approved by the Human Genome Variation Society 179 
(HGVS; www.hgvs.org/mutnomen). Further details are available in the Supplementary methods. 180 
 181 
Structural model for TPO & DUOX2 182 
The models for TPO and DUOX2 were generated using the phyre2 (Protein Homology/analogy 183 
Recognition Engine 2) web portal which predicts and analyses protein structures based on 184 
homology/analogy recognition to solved protein crystal structures (14). The figures were generated 185 
with MacPyMOL Molecular Graphics System, Schrödinger, LLC. 186 
 187 
Results 188 
Sequencing data quality 189 
Detailed information regarding individual gene coverage is summarized in the Supplementary section. 190 
In the samples sequenced by WES or HiSeq targeted sequencing panel, optimal median coverage 191 
(>30 fold) was achieved for all genes except DUOXA2 and SLC5A5 in the eleven samples screened by 192 
targeted sequencing (median coverage 5-fold and 24-fold respectively) (Supplementary Figure 1A, B). 193 
Exons screened using the MiSeq targeted sequencing panel either achieved >20-fold coverage (in 194 
 8 
house validation had demonstrated 100% sensitivity for detecting variants at this sequencing depth), 195 
or were repeated by Sanger sequencing, such that this approach was expected to be highly sensitive. 196 
In the WES and HiSeq protocols, in common with previous studies employing similar techniques, 197 
although median coverage was generally acceptable, coverage was non-uniform across individual 198 
genes (Supplementary Figure 2). This was most marked with the HiSeq targeted sequencing panel in 199 
which specific exons exhibited <10-fold coverage including DUOXA2 (exons 1, 2, 4, 5 and 6), 200 
SLC5A5 (exons 1-3, 5, 6, 11, 12 and 15), DUOX2 (exons 2, 5, 6, 8, 15 and 34), TG (exons 13, 15, and 201 
16), TPO (exons 3, 7, 8, and 16), SLC26A4 (exon 21) and IYD (exon 6). A detailed comparison of the 202 
sequencing techniques is provided in Supplementary Figure 2.  203 
 204 
Mutation frequencies (Figure 1) 205 
Forty-nine cases from thirty-four families of European, Asian, Middle Eastern and Afro-Caribbean 206 
origin were investigated and twenty-nine cases (twenty families, 59%) were considered ‘solved’ 207 
following identification of a decisive link between genotype and phenotype. In eleven ‘ambiguous’ 208 
cases (22%) it was felt that the ascertained genotype could plausibly be contributing to the phenotype, 209 
but the evidence to support a causal link was weaker than in the ‘solved’ group.  Finally, nine cases 210 
were considered ‘unsolved’ as they carried no mutations in any of the listed genes.  Detailed genetic 211 
and phenotype data is supplied in Supplementary Tables 1, 2 and 3.  212 
 213 
CH was more severe biochemically in solved cases than in unsolved or ambiguous cases (mean TSH 214 
100mU/L vs 36mU/L at diagnosis, p=0.02, Welch’s t-test) and solved cases were more frequently 215 
from consanguineous backgrounds (69% cases vs. 40% cases). This likely reflects the increased 216 
incidence of recessive disease in the presence of consanguinity, since CH- associated mutations in 217 
five of the eight targeted genes (TG, TPO, DUOXA2, SLC5A5 and SLC26A4) are usually biallelic. 218 
Cases with affected siblings were common in both solved and unsolved or ambiguous categories 219 
(79% vs. 70% cases) (Figure 1, Supplementary Tables 2, 3). 220 
 221 
‘Solved’ kindreds harbouring mutations in one gene (monogenic kindreds) 222 
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Nineteen cases had a monogenic basis of disease, most commonly involving biallelic mutations in TG 223 
(twelve cases), followed by TPO (four cases), DUOX2 (one monoallelic and one biallelic mutation) 224 
and TSHR (one case). There were no cases with CH attributable to mutations in IYD, SLC5A5 or 225 
SLC26A4 (Figure 1). 226 
 227 
TG mutations (Figure 2) 228 
TG is the secretory protein upon which thyroid hormone is synthesized, and the 12 cases with 229 
monogenic TG mutations predominantly exhibited moderate-severe CH (Figure 2). One known and 230 
three novel homozygous nonsense or frameshift mutations were identified which truncate TG before 231 
the carboxy-terminal acetyl cholinesterase (ACHE)-like domain, which has a crucial role in normal 232 
conformational maturation and intracellular trafficking of TG (F1, 2, 3, 4)  (15). Two siblings (F5 a, 233 
b) were compound heterozygous for a known nonsense mutation (p.R296*) and a rare, novel missense 234 
variant, (p.C160S) which affects a highly conserved cysteine residue in TG (GERP score 5.84). 235 
Cysteine residues within repetitive domains in TG form intramolecular disulphide bonds needed for 236 
protein folding, thus p.C160S may be deleterious to TG affecting the tertiary structure as predicted by 237 
PolyPhen (16, 17, 18). Two siblings (F7a, b) harbored the same homozygous TG splice region variant 238 
(c.638+5 G>A) inherited from heterozygous parents; although the pathogenicity of this cannot be 239 
ascertained in silico, it is unique to the affected siblings, and adjacent to a known pathogenic mutation 240 
(c.638+1G>A) (19), supporting causality, albeit in association with a mild CH phenotype. 241 
 242 
TPO mutations (Figure 3) 243 
TPO is the heme peroxidase catalyzing the final steps of thyroid hormone synthesis and biallelic 244 
mutations (Figure 3) were identified in four monogenic kindreds. These included two known 245 
pathogenic missense mutations (F16; p.R491H, F17; p.R665Q), two novel frame shift (F20; 246 
p.C808Afs*24, F16; p.A397Pfs*76) and two novel missense variants (F18; p.R291H, p.G331V) 247 
(Table 2). The p.R291H variant is predicted to disrupt a hydrogen bond network close to the TPO 248 
heme group thereby destabilizing the catalytic domain. G331 is located close to the substrate binding 249 
domain, and mutation to the larger valine amino acid will likely cause steric hindrance impeding 250 
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substrate binding (Figure 3). Two cases were compound heterozygous: F16 p.[A397Pfs*76];[R491H], 251 
associated with dyshormonogenic goitre requiring thyroidectomy and F18 p.[R291H];[G331V], who 252 
also exhibited goitre.  253 
 254 
DUOX2 mutations (Figure 4) 255 
DUOX2 is the NADPH oxidase, which generates H2O2 required for thyroid hormone biosynthesis. 256 
Two solved cases with monogenic DUOX2 mutations were identified (Figure 4), including one known 257 
heterozygous mutation (F23; p.F966Sfs*29) and one novel homozygous mutation (F24; 258 
p.L1028Afs*3), both of which would truncate DUOX2 before the NADPH oxidase domain, thereby 259 
abrogating protein function. Affected cases generally had a milder or transient (F23) CH phenotype 260 
compared with cases harbouring monogenic TG and TPO mutations. 261 
 262 
TSHR mutation 263 
A single individual from the UAE with mild CH harbored a known pathogenic heterozygous TSHR 264 
mutation (F26; p.P68S) (Supplementary table 2), previously identified in an Arab population. Parental 265 
DNA was not available, however, the mild CH phenotype was consistent with previously reported 266 
biochemistry associated with this mutation (20). 267 
 268 
‘Solved’ kindreds harboring mutations in two genes (oligogenic kindreds, Figure 5) 269 
Ten solved cases from seven families harbored digenic pathogenic variants.  These were 270 
predominantly triallelic, and most commonly comprised biallelic TG mutations in association with a 271 
monoallelic DUOX2 mutation. Such digenic mutations were detected in consanguineous Turkish 272 
kindreds F6, 8 and 9 (Figure 5). In these kindreds, although defined as variants of uncertain 273 
significance by ACMG criteria, the biallelic TG mutations were rare (p. W1051L; MAF <0.001 in 274 
1KG Europeans, and absent in all other population datasets, including ExAC East Asians) or unique, 275 
affected conserved amino acids and were predicted to be pathogenic by PolyPhen and SIFT.  In F6, 276 
two siblings (a, b) with CH were both homozygous for TG p.W1051L and p.C726Y but one sibling 277 
(F6b) harbored an additional, maternally-inherited heterozygous DUOX2 mutation (p.Q686*), 278 
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previously described in association with transient CH (21). Biochemistry at diagnosis could not be 279 
retrieved from F6b for comparison with F6a, however both presented with neonatal goitre and had 280 
similar levothyroxine requirements. Their mother exhibited adult-onset hypothyroidism of unknown 281 
etiology. Two unrelated sibling pairs also harbored homozygous TG mutations in association with a 282 
heterozygous DUOX2 mutation: TG p.1493Y and DUOX2 p.Q686* in F8 a, b and TG p.W2685L and 283 
DUOX2 R354W (predicted to perturb the DUOX2  peroxidase-like domain) in F9a, b (Figure 4). 284 
There was also a strong history of goitre (mother and maternal aunt) in F8 but maternal DNA was not 285 
available to confirm DUOX2 genotype. In all three kindreds, the most severe phenotype was observed 286 
in individuals harbouring biallelic TG or triallelic (biallelic TG and monoallelic DUOX2) mutations, 287 
however it was impossible to distinguish the effects of the mutations in the two genes reliably in these 288 
small pedigrees with limited subphenotype data.  289 
 290 
Since monogenic, heterozygous DUOX2 mutations (including p.Q686*) are frequently associated 291 
with CH, we hypothesized that an additive phenotypic contribution of all three mutations was very 292 
plausible. Calculation of the number of East Asian individuals in the ExAC database (n=8,654) 293 
harburing similarly rare, predicted damaging variants in DUOX2 yielded a population mutation 294 
frequency of 0.06%. The observed proportion of TG mutation carriers with a monoallelic DUOX2 295 
variant in our cohort (8.8% families) was therefore significantly higher (p=0.0233, Fisher’s exact one-296 
tail test), supporting a potential phenotypic contribution of the DUOX2 mutation in these individuals. 297 
Much larger cohorts of sequenced CH individuals will be required to assess the phenotypic 298 
consequences of digenicity in CH thoroughly. 299 
 300 
Biallelic mutations in TPO were identified in two kindreds in addition to heterozygous known 301 
SLC26A4 mutations, previously associated with recessive disease: F19a: TPO p.R584Q 302 
(homozygous) and SLC26A4 p.N324Y (heterozygous); F19b: TPO p.R584Q (homozygous) and 303 
SLC26A4 p.I713M (heterozygous); F21: TPO p.[E17Dfs*77];[Y453D] (compound heterozygous) and 304 
SLC26A4 p.E384G (heterozygous) (Figure 5). The novel TPO p.R584Q missense variant is predicted 305 
to perturb polar contacts possibly affecting the catalytic domain (Figure 4).  306 
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The occurrence of Pendred syndrome usually mandates biallelic SLC26A4 mutations, and manifests 307 
universally with congenital or postnatal progressive sensorineural hearing loss, whereas thyroid 308 
dysfunction is usually mild or absent. In both these kindreds, only the biallelic TPO mutations 309 
segregated with CH; this was severe whereas hearing was normal. In F11, a known homozygous 310 
pathogenic TPO mutation (p.R491H) was inherited together with a heterozygous TG variant 311 
(p.Q1644E). Since biallelic inheritance is also usually required for CH due to TG mutations, these 312 
observations suggest the TPO mutations are predominant drivers of the CH phenotype in these three 313 
kindreds, although we cannot definitively exclude a contribution of the heterozygous SLC26A4 or TG 314 
mutation. Comparison with population mutation frequencies in TG and SLC26A4 in the ExAC cohort 315 
(non-Finnish Europeans, N=66,740), suggested that congruence of TPO mutations with TG or 316 
SLC26A4 mutations was not increased in our cohort (p=0.2280, p=0.0951 respectively). 317 
 318 
Detailed investigation of the contribution of oligogenicity to genotype-phenotype variability mandates 319 
the study of large kindreds with a spectrum of genotypes, e.g. F10 (Figure 5). In this large, 320 
consanguineous Pakistani kindred the proband harbours a known pathogenic DUOX2 mutation 321 
(p.Q570L, previously published in 8). Homozygosity for this mutation segregates with permanent CH 322 
(F10a), whereas DUOX2 p.Q570L heterozygotes exhibit either euthyroidism or transient CH. Two 323 
novel, rare TG variants (p.L2547Q, predicted to be pathogenic by PolyPhen and SIFT, and p.R1691C, 324 
of less certain significance) were also identified in this kindred, yet neither of these variants 325 
segregated with transient CH in the DUOX2 p.Q570L heterozygotes, suggesting digenic mutations in 326 
the genes screened did not explain the phenotypic variability associated with this genotype. 327 
 328 
Unsolved or ambiguous kindreds  (Figure 1, Supplementary Table 3) 329 
This group included two cases harboring heterozygous pathogenic TG variants; a novel nonsense 330 
mutation in F13 (p.Q771*) and a previously described missense mutation in F12 (p.Q870H). An 331 
additional case was heterozygous for a frameshift mutation in TPO (p.E510Afs*14, F22). Previous 332 
reports of CH due to TG and TPO mutations most commonly involve biallelic mutations, therefore it 333 
is unclear whether the mild or subclinical hypothyroidism was attributable to the monoallelic 334 
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mutation or whether they harbored a second ‘hit’ not detected by our sequencing methods. Other 335 
cases in this category harbored novel heterozygous TG missense (p.Y759C, F14) or splice region 336 
(c.3433+3_3433+6delGAGT, F15) variants, a novel heterozygous DUOX2 variant (p.R764W, F25) 337 
inherited from a healthy parent and a homozygous DUOXA2 splice site (c.555-5G>A) variant for 338 
which in silico predictions were inconclusive (F27). Nine cases (seven families) remained completely 339 
unsolved with no likely disease-causing variants identified. Copy number variant (CNV) analysis was 340 
undertaken in individuals who had undergone whole exome sequencing: F13, 15, 33 (ambiguous or 341 
unsolved cases) and F3, 6-10 (solved cases), however no rare CNVs were identified that segregated 342 
with disease phenotype in each pedigree. 343 
 344 
Discussion 345 
 346 
In this study, next-generation sequencing technologies enabled efficient screening of eight genes 347 
associated with CH and GIS in forty-nine cases from the UK, Turkey, Middle East and Asia, and with 348 
a spectrum of biochemical phenotypes.  In addition to single-gene mutations, the contribution of 349 
oligogenic variants was assessed. Previous genetic evaluations of cohorts of CH with GIS have been 350 
less comprehensive, screening fewer genes, or fewer cases with restricted ethnicities (6, 9, 22, 23). 351 
The only large-scale multiplex study in CH did not select cases on the basis of thyroid morphology 352 
and excluded TG, SLC26A4 and IYD from its sequencing panel (11). Direct sequencing of DUOX2, 353 
TG, TPO and TSHR has been undertaken in 43 Korean CH cases with GIS (6); in common with our 354 
study, only around 50% of cases harbored causative, pathogenic variants in one or more genes. 355 
 356 
The relative frequency of mutations in known CH causative genes depends on selection criteria and 357 
ethnic origin of the cohort (24, 6). Our cohort included individuals of diverse ethnicities, in whom the 358 
biochemical diagnosis of CH was achieved using different, country-specific, screening protocols, or 359 
following neonatal or early childhood presentation with clinical hypothyroidism. These multiple 360 
variables preclude detailed comparison of relative mutation frequencies with other studies of 361 
populations with more uniform ethnicity or biochemical diagnostic approach. The heterogeneous 362 
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population screened in this study also mandated the use of ethnically-matched controls in order to 363 
prevent ‘false-positive results’ due to incorrect classification of ethnically-specific SNP’s as 364 
pathogenic mutations. The paucity of West Asian exomes in publically-accessible databases 365 
precluded this for 17 non-Turkish West Asian cases. However, the large number of controls used 366 
(~80,000) and the fact that 8 of the 10 solved West Asian cases harboured truncating or previously 367 
reported CH-associated mutations, made false positive results unlikely. 368 
 369 
In our study, mutations were most frequently found in TG, followed by TPO, whereas DUOX2 370 
mutations were relatively infrequent compared with findings by Jin et al (mutations in 35% all cases), 371 
probably reflecting the higher prevalence of DUOX2 mutations in individuals of East Asian ethnicity, 372 
who were poorly represented in our study (6, 11, 25). No definitively pathogenic mutations were 373 
found in DUOXA2, IYD or SLC5A5, which is in keeping with previous reports suggesting that these 374 
are rare genetic causes of dyshormonogenesis, with the exception of a recurrent DUOXA2 mutation in 375 
Korean cases (26, 11). The paucity of TSHR mutations in a CH cohort with GIS is surprising; 376 
however, the high incidence of consanguinity in our cohort predicts occurrence of biallelic mutations 377 
that, in the case of TSHR, may cause thyroid hypoplasia, with such cases possibly being excluded 378 
from recruitment to our GIS CH cohort (6, 27). Despite unselected recruitment of either sporadic or 379 
familial cases, our cohort was greatly enriched for familial CH (76% cases), and consanguinity, which 380 
may have increased the percentage of cases harboring an underlying genetic etiology.  In a standard 381 
UK clinic population with a greater proportion of sporadic, non-consanguineous cases, the proportion 382 
of mutation-negative cases could be higher.  383 
 384 
Interpretation of novel genetic variants requires functional studies in vitro (or in vivo evidence of 385 
impaired TSH-stimulated mutant thyroglobulin production for TG mutations) in order to confirm 386 
pathogenicity (18). Although such analyses were not undertaken, the novel variants identified are rare, 387 
segregate with phenotype, and have strong bioinformatic or structural (TPO) predictions of 388 
pathogenicity, supporting a causal role. Moreover, the location of novel variants in TPO (heme-389 
binding region or substrate-binding region) and DUOX2 (R354W; peroxidase-like domain) mirrors 390 
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that of previously described pathogenic mutations. Analysis of novel variants in TG is hindered by an 391 
incomplete knowledge of its functional domains or crystal structure, but those identified affect similar 392 
regions to previously documented mutations (N-terminal cysteine-rich repetitive elements, C-terminal 393 
ACHE-like domain) also supporting causality (8, 16, 18, 28).  394 
 395 
The associated clinical phenotypes in our mutation-positive patients were similar to published cases. 396 
TG mutations may result in euthyroid goitre and mild or severe hypothyroidism (18), and monoallelic 397 
and biallelic DUOX2 mutations may both cause permanent or transient CH (8, 21, 23, 25). Even TPO 398 
mutations, although classically associated with total iodide organification defects, can cause milder 399 
phenotypes (28). Solved cases usually had a more severe phenotype than unsolved or ambiguous 400 
cases, however the latter group included four cases of subclinical or mild CH harbouring 401 
heterozygous mutations in TPO or TG. Such monoallelic mutations have previously been described in 402 
association with CH, but are usually assumed to coexist with an additional undetected CNV, intronic 403 
or regulatory mutation on the other chromosome (16, 24, 29). This may be the case in our patients as 404 
well; our sequencing techniques would not have detected mutations in non-coding regions of the 405 
genome and although CNVs were not detected in F15, 13 and 33, they could not be excluded in the 406 
remaining families. Our observations highlight the fact that mutations in TPO or TG may underlie 407 
subclinical hypothyroidism as well as cases with overt CH. Despite elevated TSH levels, several of 408 
our non-TSHR mutation positive cases (mainly detected in the neonatal period) did not exhibit goiter. 409 
Quantitation of thyroid volume radiologically at this age is technically challenging, such that mild 410 
thyroid enlargement may not have been detected. However, TSH-driven goitrogenesis in these cases 411 
will have been dependent on fetal TSH levels – whose role in thyroid follicular cell growth remains 412 
unclear. In common with our findings, others have demonstrated that dyshormonogenetic CH, even 413 
associated with total iodide organification defect, is not always associated with thyroid enlargement   414 
(30). 415 
 416 
Oligogenicity has often been proposed to underlie the intrafamilial variability seen in known genetic 417 
causes of CH, especially in association with DUOX2 mutations (8). The Pax8/Titf1 murine model 418 
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exemplifies the role of polygenicity in thyroid dysgenesis, since only mice doubly heterozygous for 419 
the two null alleles and bred on a C57BL/6 background exhibit a phenotype (31). Despite reports of 420 
digenic GIS cases in the literature, pedigree studies have either not been performed (11, 6), or have 421 
not confirmed a genotype-phenotype correlation (12). Our study detected likely pathogenic variants in 422 
more than one CH-associated gene, especially in consanguineous kindreds, most commonly involving 423 
TG and DUOX2. It is possible that this is a conservative estimate of the frequency of oligogenicity in 424 
CH with GIS; the high percentage of consanguinity in our study facilitates identification of potentially 425 
pathogenic variants in a disease model with recessive inheritance, but also increases the likelihood of 426 
detecting variants which are contributory to the CH phenotype but not causative, due to the 427 
occurrence of genomic regions with loss of heterozygosity involving CH-associated genes. 428 
Accordingly, we cannot discount the possibility that some of our monogenic, consanguineous, 429 
‘solved’ cases harbour additional mutations in genes which were not screened in our study, that could  430 
contribute to the CH phenotype. Small pedigree sizes, poor information about mutation frequencies in 431 
populations matched to our CH cases, and a paucity of subphenotype data preclude definitive 432 
statements regarding the relative aetiological contribution of digenicity in CH. Further studies with 433 
large pedigrees and clear phenotypic variability are required to ascertain the role of polygenic 434 
modulators in CH with GIS. Alternative candidate genes involved in the same biological pathways as 435 
known causative genes may be implicated, either exacerbating or playing a compensatory role in the 436 
context of loss-of-function mutations. Examples include DUOX1, DUOXA1, and NOX, which are also 437 
involved in H2O2 production and whose expression may be upregulated in the context of DUOX2 438 
deficiency (12, 32).  439 
 440 
It is conceivable that despite adequate median coverage, non-uniform coverage of genes could have 441 
resulted in failure to detect variants. This is most likely to be significant for the eleven cases (eight 442 
families) in which coverage of specific exons was <10 fold (predominantly affecting DUOXA2 and 443 
SLC5A5). Suboptimal coverage of these regions raises the possibility of a Type II error. However, 444 
undetected variants in these cases are unlikely to affect the conclusions of this study since five cases 445 
harbored mutations which explained their CH (F26, F2a, b, F11, F17), and two ambiguous cases 446 
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harbored heterozygous TG variants (F12 a, b). Additionally, although the study was not designed to 447 
allow direct comparison of different sequencing methods, the rate of causative mutations in cases 448 
screened using either the most sensitive technique (MiSeq targeted sequencing, in which exons with 449 
<20 fold coverage were individually re-sequenced using Sanger sequencing) or WES, was similar and 450 
supported our conclusion that ~ 40% cases are unsolved. Previous studies have also reported 451 
considerable variability in uniformity and depth of coverage across the exome, and this data, together 452 
with our sequencing depth analysis, highlights a limitation of targeted sequencing, which may impact 453 
and limit variant identification (33). High-depth, whole-genome sequencing can improve exon 454 
coverage and the advent of recent sequencing technologies (such as the Illumina X10 system) make 455 
this possible at large scale.  456 
 457 
The aetiology of CH with GIS remains elusive and factors other than known dyshormonogenesis-458 
associated genes or the TSHR must be implicated. CH with GIS may be transient, and most of our 459 
cases did not undergo a formal trial off levothyroxine withdrawal. However, requirement for ongoing 460 
levothyroxine replacement in significant dosage, or continuing TSH elevation, suggested persistent 461 
CH in at least twelve unsolved cases. Biochemical CH did tend to be more severe in genetically-462 
ascertained cases, which argues against the routine screening of TG and TPO in milder GIS CH cases. 463 
Iodine status was not assessed; however the high familial component in the unsolved case category 464 
favors an etiological contribution of genetic factors rather than environmental modulators, including 465 
regulatory region or intronic mutations, or CNVs in the genes screened. Genes associated with 466 
syndromic CH (eg GLIS3, GNAS), were not analysed. Not quantitating thyroid gland size formally 467 
might have failed to ascertain cases with mild thyroid hypoplasia, harbouring mutations in some 468 
thyroid-dysgenesis associated genes (eg PAX8, Nkx2-1). Our aim in using the HiSeq targeted 469 
sequencing and MiSeq protocols was to exclude mutations in known CH-associated genes in order to 470 
identify a smaller, mutation-negative cohort, which could then be analysed by WES. Thus, future 471 
studies with WES/WGS (whole genome sequencing) in familial cases may identify novel genetic 472 
aetiologies for CH with GIS, elucidating novel pathways in thyroid development and physiology.  473 
 474 
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 641 
Figure Legends 642 
Figure 1 643 
Schematic illustrating case selection, variant filtering and distribution of mutations in the cohort of 644 
patients studied with CH and GIS. ‘Solved’ cases refers to cases in whom a definitive link was 645 
established between genotype and CH phenotype. In ‘ambiguous’ cases, the ascertained genotype 646 
could plausibly be contributing to the phenotype, but the evidence to support a causal link was weaker 647 
than in the ‘solved’ group, and ‘unsolved’ cases carried no mutations in any of the listed genes. The 648 
number of cases harbouring monoallelic or biallelic mutations in each gene are listed beneath the 649 
corresponding gene name for the ‘solved’ cases. Numbers in the intersect between circles denote 650 
triallelic cases harbouring mutations in both genes. In the ‘ambiguous’ category, the number of 651 
mutations in each gene are classified by mutation type beneath the relevant gene name; all except 652 
DUOXA2 were monoallelic. ‘Solved’ and ‘ambiguous’ or ‘unsolved’ cases were equally likely to be 653 
familial, but CH was generally more severe in the ‘solved’ cases. Splice; splice region variant, fs*; 654 
frameshift mutation resulting in a premature stop codon, VUS; variant of uncertain significance. 655 
 656 
Figure 2 657 
Summary of TG mutations identified in the study and the associated biochemical phenotype. CH 658 
severity is classified according to ESPE criteria on the basis of serum fT4 levels; severe, <5, moderate 659 
5 to <10, and mild > 10 pmol/l, respectively (33) and pathogenicity is predicted according to ACMG 660 
guidelines (34). A schematic of the TG protein illustrates the position of the mutations relative to the 661 
key structural domains of TG including the repetitive type 1, 2 and 3 cysteine-rich regions, 662 
acetylcholinesterase homology (ACHE-like) domain and hormonogenic domains. Known mutations 663 
are shown in grey, novel mutations in black. *; cases for which complete biochemical data at 664 
diagnosis is not available. CH severity refers to sibling. bs; blood spot. 665 
 666 
 667 
 668 
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 669 
Figure 3 670 
Summary of TPO mutations identified in the study and the associated biochemical phenotype. CH 671 
severity is classified according to ESPE criteria (33) and pathogenicity is predicted according to 672 
ACMG guidelines (34). The effect of the novel missense mutations was modelled using the phyre2-673 
server. Figures in the top row show the wild-type (WT) model, with amino acids of interest in green, 674 
figures on bottom row show the model with the mutant amino acid (orange); local polar contacts are 675 
shown with black broken lines. 676 
The R291H and R584Q mutations affect amino acids contributing to an intensive network of H-bond 677 
contacts close to the catalytic domain involving the heme-group. R291 makes polar contacts with 678 
R585 and R582, interacting directly with the heme-group and R584 makes direct polar contacts with 679 
the heme-group itself as well as P203 and D633. The mutations R291H (increased hydrophobicity) 680 
and R584Q (resulting in a smaller polar group) are likely to disrupt polar contacts affecting local 681 
structure and are predicted to affect catalytic activity.  682 
The G331V mutation affects local space filling with the larger valine predicted to impair substrate 683 
binding by displacement of the nearby helix and/or disruption of polar contacts (orange amino acids, 684 
H2O molecules in blue), affecting the local structure of TPO. 685 
 686 
Figure 4 687 
Summary of DUOX2 mutations identified in the study and the associated biochemical phenotype. CH 688 
severity is classified according to ESPE criteria (33) and pathogenicity is predicted according to 689 
ACMG guidelines (34). Mutation position is illustrated using a schematic representation of the 690 
domain structure of the DUOX2 protein. Known mutations are shown in grey and novel mutations in 691 
black.  692 
The structural model of the peroxidase domain suggests that R354 is part of an intensive hydrogen 693 
network. The novel missense mutation R354W replaces the hydrophilic Arginine by the hydrophobic 694 
tryptophan disrupting this network and also results in a possible repositioning of the loop containing 695 
 26 
R354 and C351, which mediates interactions between the peroxidase domain and extracellular loops 696 
obligatory for DUOX2 function. 697 
Figure 5 698 
Genotype-phenotype segregation in six kindreds with oligogenic variants. Horizontal bars denote 699 
individuals who have been genotyped. Black shading denotes homozygous individuals and half-black 700 
shading denotes heterozygotes for TG mutations (F9, F6, F8), TPO mutations (F19, F21) and DUOX2 701 
mutations (F10). Potential oligogenic modulators are included by aligning genotype and phenotype 702 
data with the individual to whom they refer in the pedigree. *; cases for whom complete biochemical 703 
data at diagnosis is not available (F6b, F8a) and CH severity refers to sibling. 704 
In F10, black, half-black and white shading denote the DUOX2 genotype (Q570L homozygous, 705 
heterozygous or wild-type respectively). The pedigree is annotated with TG genotype in those cases 706 
harbouring variants (L2547Q, R1691C), and phenotype (euthyroid, transient or permanent CH) with 707 
venous screening TSH results for CH cases. Cases annotated (euthyroid) were born in Pakistan and 708 
although euthyroid in adulthood, the fact that they were not screened neonatally for CH may have 709 
precluded detection of transient CH.  710 
 711 
Supplementary Figure 1 712 
Proportion of gene length covered at various depth intervals. (A) WES (B) HiSeq targeted sequencing 713 
panel. SAMtools mpileup was used to determine the depth at each base within every bait region of 714 
every gene for all samples. The median coverage across samples per gene (at exonic sequences only) 715 
is represented on top of each bar. 716 
 717 
Supplementary Figure 2  718 
Table describing translated exons with inadequate median sequencing depth (<10 fold) in the 719 
samples sequenced by WES, HiSeq and MiSeq targeted sequencing and comparing the 720 
number of cases solved by each method 721 
 722 
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Supplementary Table 1  723 
Known and novel mutations detected in the eight genes screened with the predicted consequences by 724 
SIFT (‘Sorting Tolerant from Intolerant’ Algorithm, Ng 2001) and PolyPhen (Polymorphism 725 
Phenotyping v2, Adzhubei 2010) and the Genomic Evolutionary Rate Profiling (GERP) score 726 
(Davydov 2010). c.DNA; Variant represented in the HGVS notation at the coding DNA level for a 727 
transcript. MAF (minor allele frequency) refers to the maximum MAF in all the databases 728 
interrogated, with the database from which the MAF is derived in brackets. Blank entries denote 729 
unique variants. NA; Not available 730 
1000 Genomes Phase I (1KG_AF), NHLBI GO Exome Sequencing Project 6,500I (ESP_AF), 731 
UK10K low-coverage study (UK10K), other UK10K whole-exome sequencing studies (UK10K 732 
cohorts) and Exome Aggregation Consortium r0.3 (ExAC).  733 
 734 
Supplementary Table 2  735 
Biochemical, radiological and demographic details at diagnosis in cases in whom mutations are 736 
detected which are thought to explain the CH phenotype. The column entitled ‘Background’ indicates 737 
the ethnic background. The column entitled ‘Diagnosis’ includes age at diagnosis as well as indicating 738 
the country in which newborn screening was performed for cases detected by this method. TSH 739 
values are venous unless otherwise stated; F20 was on L-T4 at the time of sampling. C; known to be 740 
consanguineous, bs; blood spot, U; ultrasound, I; isotope scan. KSA; Saudi Arabia, A-C; African –741 
Caribbean, NSP; newborn screening programme, het; heterozygous mutation, hom; homozygous 742 
mutation, wt; wild-type, sib; sibling, T.CH; transient CH, NA; Not available, L-T4; levothyroxine 743 
Additional clinical features: F17: Hypospadias, hand contractures, hypertrichosis, hyperpigmentation, 744 
gynaecomastia, F9a, b:? Cohen syndrome (congenital glucosidation defect and neurometabolic 745 
disease), F9a:  Bicuspid aortic valve, F21: Polydactyly, macroglossia. F24: the mother was screened 746 
from this highly consanguineous family, and the DUOX2 mutation identified in heterozygosity; this 747 
was homozygous in her affected daughter. Newborn screening blood spot cut offs were as follows: 6-748 
10mU/L (UK), 10mU/L (UAE) or cord blood TSH 40mU/L (Oman). Childhood TSH normal range 749 
was 0.35-5.5mU/L. 750 
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Supplementary Table 3 751 
Biochemical, radiological and demographic details at diagnosis in cases in whom mutations are 752 
detected which are thought significant without fully explaining the CH phenotype (ambiguous cases), 753 
and cases in whom no significant mutations were found. The column entitled ‘Background’ indicates 754 
the ethnic background. The column entitled ‘Diagnosis’ includes age at diagnosis as well as indicating 755 
the country in which newborn screening was performed for cases detected by this method. TSH 756 
values are venous unless otherwise stated. C; known to be consanguineous, bs; blood spot, U; 757 
ultrasound, I; isotope scan, KSA; Saudi Arabia, NSP; newborn screening programme, het; 758 
heterozygous mutation, hom; homozygous mutation, NA; Not available. F25*; No investigations but 759 
had goitre, and on 50mcg levothyroxine aged 5. Two siblings had dyshormonogenesis with TSH>100, 760 
fT4 6.9, and avid uptake in a normally-sited gland (i). 761 
Additional clinical features: F12a,b: IUGR, F14a,b: Papillon-Lefevre syndrome, F21, postaxial 762 
polydactyly, F27: Monogenic skeletal dysplasia unrelated to CH, F32: Metabolic acidosis, 763 
developmental delay, F34: Hypospadias, undescended testes, laryngomalacia, hypertelorism. 764 
Newborn screening blood spot cut offs were as follows: 6-10mU/L (UK), 10mU/L (UAE) or cord 765 
blood TSH 40mU/L (Oman). Childhood TSH normal range was 0.35-5.5mU/L. 766 
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